# US 2021/0277095 A1 · Fc VARIANTS WITH ALTERED BINDING TO FcRn

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277095 A1
- Document ID: US20210277095A1
- Status: Published application
- Kind: A1
- Application number: 17/079,299
- Filed: 2020-10-23
- Published: 2021-09-09
- Earliest claimed: 2007-10-31
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Aaron Keith Chamberlain; Bassil Dahiyat; John R. Desjarlais; Sher Bahadur Karki; Gregory Alan Lazar
- Web page: https://patentgrep.com/patent/US20210277095A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2893: {against CD52}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/32: against translation products of oncogenes
- C07K 16/4291: {against IgE}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.

## Claims

### Claim 1

An anti-TNF antibody comprising:
a. two identical heavy chain polypeptides, each having the amino acid sequence of SEQ ID NO: 29; and
b. two identical light chain polypeptides, each having the amino acid sequence of SEQ ID NO: 23.

### Claim 2

A nucleic acid comprising:
a. a first polynucleotide encoding a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 29; and/or
b. a second polynucleotide encoding the a chain polypeptide having the amino acid sequence of SEQ ID NO: 23.

### Claim 3 (depends on 2)

The nucleic acid of claim 2, wherein the nucleic acid is an expression vector.

### Claim 4

An expression vector system comprising:
a. a first expression vector comprising a first polynucleotide encoding a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 29; and
b. a second expression vector comprising a second polynucleotide encoding the light chain polypeptide having the amino acid sequence of SEQ ID NO: 23.

### Claim 5

A host cell comprising
a. a first polynucleotide encoding a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 29; and
b. a second polynucleotide encoding the a chain polypeptide having the amino acid sequence of SEQ ID NO: 23.

### Claim 6 (depends on 5)

A method of producing an anti-TNF antibody comprising culturing the host cell of claim 5 under conditions such that the anti-TNF antibody is expressed, and recovering the anti-TNF antibody.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method of treating an autoimmune disease in a subject in need thereof comprising administering to the subject the antibody of claim 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the autoimmune disease is selected from rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and Crohn's disease (CD).
